Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II drugs for Hidradenitis Suppurativa have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ruxolitinib phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ruxolitinib phosphate overview
Ruxolitinib (INCB18424, Jakafi, Jakavi) is an anti neoplastic, immunomodulating and anti inflammatory agent. It is formulated as tablets for oral administration. Ruxolitinib is indicated for patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis. It is also indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. Ruxolitinib is indicated as emergency use for the treatment of COVID-19. Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies.
Ruxolitinib phosphate is under development for the treatment of vitiligo, discoid lupus erythematosus (DLE), metastatic advanced cutaneous squamous cell carcinoma, idiopathic hypereosinophilic syndrome, atopic dermatitis, hemophagocytic lymphohistiocytosis, COVID-19 patients with defined hyperinflammation and primary eosinophilic disorders, polycythemia vera, relapsed/refractory multiple myeloma, Hodgkin lymphoma, relapsed/refractory acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myelomonocytic leukemia (CMML), chronic myelocytic leukemia (CML), bronchiolitis obliterans syndrome, myelodysplastic syndrome, acute myelocytic leukemia (AML), Myelofibrosis, Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease (GVHD), diffuse large B-cell lymphoma, essential thrombocythemia, peripheral T-cell lymphomas, head and neck squamous cell carcinoma including oral cavity cancer, oropharngeal cancer, hypopharyngeal cancer and laryngeal cancer, CLL as first line therapy and breast biopsy showing ADH (atypical ductal hyperplasia), ALH (atypical lobular hyperplasia), LCIS (lobular carcinoma in situ), or DCIS (ductal carcinoma in situ), inflammatory triple negative breast cancer, plaque psoriasis, chronic active Epstein-Barr virus infection (CAEBV), Lichen sclerosus, unspecified dermatological disorders (cutaneous lichen planus), hidradenitis suppurativa and Coronavirus infections and cytokine storm. It is administered through cutaneous route.
It was also under development for early myelofibrosis, cancer cachexia, metastatic prostate cancer, rheumatoid arthritis, metastatic colorectal cancer and metastatic adenocarcinoma of the pancreas, non-small cell lung cancer, metastatic HER2 negative breast cancer, lung adenocarcinoma, adenocarcinoma, metastatic colorectal cancer, acute respiratory distress syndrome, chronic hand eczema and thalassemia.
Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
For a complete picture of Ruxolitinib phosphate’s drug-specific PTSR and LoA scores, buy the report here.